Blood pressure control in patients receiving bevacizumab in an outpatient cancer center

Sal Bottiglieri, Benyam Muluneh, Stephanie Sutphin, Lew Iacovelli, Val Adams

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Purpose. Hypertension is a common adverse effect of vascular endothelial growth factor (VEGF) signaling inhibitors, such as bevacizumab, with an incidence upwards of 35%. The management of bevacizumab-induced hypertension is important in order to avoid dose interruption/discontinuation and/or end organ damage. The efficacy of antihypertensive medications for this cause of hypertension has not been demonstrated. This study seeks to determine if antihypertensives are effective in treating anti-VEGF-induced hypertension from bevacizumab and determine which classes of antihypertensive agents are effective.Methods. A retrospective review of all patients who received bevacizumab between January 2007 and September 2009 at two medical centers was conducted. Patients were included if they experienced new onset or exacerbation of preexisting hypertension, during bevacizumab treatment. Efficacy of antihypertensives was determined by recording a 28-day change in systolic blood pressure from the initiation or dose increase of individual antihypertensive medications. Secondary endpoints included an efficacy analysis of antihypertensive classes.Results. Five-hundred thirteen patients were identified as receiving bevacizumab during the indicated time period. Fifty-seven patients met the full inclusion/exclusion criteria for analysis. The average systolic blood pressure declined by 23mmHg with 4 weeks of treatment (p<0.0001). Each class had a statistically significant decline in systolic blood pressure of 15.5-57mmHg with the exception of diuretics and a group of miscellaneous antihypertensives.Conclusions. This is the first data that demonstrates individual classes of antihypertensives are effective in bevacizumab-induced hypertension. Most antihypertensives were effective in reducing blood pressure, with the exception of diuretics and miscellaneous antihypertensives, which may be due to a limited sample size.

Original languageEnglish
Pages (from-to)333-338
Number of pages6
JournalJournal of Oncology Pharmacy Practice
Issue number4
StatePublished - Dec 2011


  • Bevacizumab
  • angiogenesis
  • blood pressure
  • hypertension

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Blood pressure control in patients receiving bevacizumab in an outpatient cancer center'. Together they form a unique fingerprint.

Cite this